2022. A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC). SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s95. DOI:https://doi.org/10.25251/skin.6.supp.95.